К содержанию
РецензированоEN2025

HORMONAL INFLUENCE ON BREAST CANCER DEVELOPMENT AND PROGRESSION: MOLECULAR INSIGHTS AND THERAPEUTIC ADVANCES

HORMONALINFLUENCE ONBREASTCANCERDEVELOPMENT AND · PROGRESSION:MOLECULARINSIGHTS AND THERAPEUTICADVANCES · Shafkatilloyeva Kamola G'anijon kizi (5thyear studentsof theFaculty ofPediatrics of Samarkand StateMedical University) · Abdusalomova O'g'iloy Sanjarkizi (5thyear studentsof theFaculty ofPediatrics of Samarkand StateMedical University) · Eshmamatova FayyozaBoymamatovna (5thyear studentsof theFaculty ofPediatrics of Samarkand StateMedical University) · XosilovaUg'iloy Ravshankizi (3thyear studentsof theFaculty ofPediatrics of Samarkand StateMedical University) · Elmurodova NoilaHusniddin kizi (3thyear studentsof theFaculty ofPediatrics of Samarkand StateMedical University)

Международный мультидисциплинарный журнал исследований и разработок · 12 · 2025

Аннотация

Breast cancer is the most commonly diagnosed malignancy among women globally, with hormonal factors playing a pivotal role in its pathogenesis and progression. Estrogen and progesterone, the primary female sex hormones, are deeply implicated in tumor development through their interaction with nuclear hormone receptors and subsequent gene regulation. This article explores the molecular mechanisms by which hormones influence breast cancer initiation and evolution. It also reviews current hormonal therapies, including selective estrogen receptor modulators (SERMs), aromatase inhibitors, and emerging targeted approaches. Moreover, recent statistics, clinical trial outcomes, and global treatment disparities are examined to present a comprehensive understanding of hormone-driven breast cancer management. Keywords: Breast cancer, estrogen, progesterone, hormone receptors, SERMs, aromatase inhibitors, hormonal therapy, molecular oncology, targeted treatment, endocrine resistance. Introduction:Breast cancer remains the leading cause of cancer-related death among women, accounting for nearly 15% of all cancer deaths in females worldwide. According to the World Health Organization (WHO), more than 2.3 million women were diagnosed with breast cancer in 2022, with approximately 685,000 deaths globally. A significant proportion — over 70% — of breast cancer cases are hormone receptor-positive (HR+), indicating that the tumors grow in responseto estrogen and/orprogesterone signaling. Hormones, especially estrogen and progesterone, are central to breast development, cellular proliferation, and tissuehomeostasis. However, dysregulation ofhormonal pathways can lead to uncontrolled cellular growth, genomic instability, and ultimately malignant transformation. This article delves into the intricate hormonal mechanisms that fuel breast cancer and outlines therapeutic strategies that target thesepathways for betterpatient outcomes. HormonalPathways inBreast CancerDevelopment. Estrogen and progesterone exert their effects through binding to their respective receptors — estrogen receptor (ER) and progesterone receptor (PR) — located within the nuclei of breast epithelial cells. Upon binding, these receptors act as transcription factors, regulating genes associated withcell growth, survival, and differentiation. In hormone-sensitivebreast cancers, increased estrogen exposure— whether endogenous (early menarche, late menopause) or exogenous (hormone replacement therapy, oral contraceptives) — is associated with heightened cancer risk. Estrogen promotes proliferation by upregulating 454 INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR RESEARCH & DEVELOPMENT SJIF2019:5.2222020:5.5522021:5.6372022:5.4792023:6.5632024:7,805 eISSN:2394-6334 https://www.ijmrd.in/index.php/imjrd Volume12,issue06(2025) cyclin D1, c-myc, and BCL-2, and downregulating tumor suppressors like p53. Furthermore, estrogen can induce mutations through oxidative stress and generate a pro-inflammatory microenvironment favorable totumordevelopment. Progesterone, although more controversial in its role, also modulates cellular proliferation, particularly in the luteal phase. Recent evidence suggests that progesterone can either promote or inhibit tumor progression depending on the receptor isoform expression (PR-A vs PR-B) and thepresenceof co-regulatory proteins. MolecularSubtypes of Hormone-ResponsiveBreast Cancer Breast cancer is aheterogeneous disease with distinct molecularsubtypes: Luminal A: ER+ and/orPR+, HER2-, lowKi-67 —most hormone-responsive, better prognosis. Luminal B: ER+ and/or PR+, HER2±, high Ki-67 — more aggressive, partial hormone response. HER2-enriched: ER-/PR-, HER2+ — less hormone-sensitive, treated with HER2-targeted therapy. Triple-negative: ER-/PR-/HER2- — not hormone-driven, requires chemotherapy or immunotherapy. Luminal A and B subtypes, which constitute over 60% of breast cancer cases, are the primary targets ofhormonal therapies. Current Hormonal Therapies andMechanisms Hormonal therapy is the mainstay treatment for HR+ breast cancer. These therapies either block hormonereceptors or reduce hormone production. The maincategories include: 1.SelectiveEstrogen Receptor Modulators (SERMs) Tamoxifen, the most well-known SERM, binds to estrogen receptors and inhibits transcriptional activation in breast tissue. It reduces the risk of recurrence and mortality by over 30%whenused for5–10years post-surgery in ER+patients. 2.Aromatase Inhibitors (AIs) Drugs like anastrozole, letrozole, and exemestane block the aromatase enzyme that converts androgens to estrogen, effectively lowering estrogen levels in postmenopausal women. AIs are now preferred over tamoxifen in many postmenopausal settings due to better disease-free survival rates. 3.SelectiveEstrogen Receptor Degraders (SERDs) Fulvestrant is a SERD that not only blocks the ER but also accelerates its degradation. It is effective in advanced or metastatic HR+ breast cancer, particularly after resistan

Доказательный фрагмент

«Breast cancer is the most commonly diagnosed malignancy among women globally, with hormonal factors playing a pivotal role in its pathogenesis and progression.»

Образец извлечения

Демо-превью

Breast cancer is the most commonly diagnosed malignancy among women globally, with hormonal factors playing a pivotal role in its pathogenesis and progression. Полный текст публикации CiteX не хранит — доступ к первоисточнику открывается по DOI согласно лицензии издателя и выбранному плану.

DOI не указан
Цитирований
0
Тип
Журнал
Страна
Узбекистан
Ключевые слова
Breast cancer, estrogen, progesterone, hormone receptors, SERMs, aromatase
Спросить CiteX об этой работе

Смежные источники